Breakthrough Device Designation: FDA Fast-Track and Medicare Payment Realities

2026-09-10 · Caduvo Team

FDA Breakthrough Device Designation speeds up review but does not guarantee Medicare coverage. Learn the eligibility criteria, the real benefits during review, and how to plan for reimbursement under the transitional coverage for emerging technologies pathway.

You have a device that treats a life-threatening condition, and the data from your first-in-human trial looks strong. Your board wants to know whether the FDA Breakthrough Devices Program can shorten the path to market and—more importantly—get Medicare to pay faster. The short answer: yes to the review advantages, but no to automatic coverage. Here is exactly what the designation delivers, what it requires, and how to think about reimbursement before you submit the request.

What the Breakthrough Device Designation Is (and Isn’t)

The Breakthrough Devices Program, created under the 21st Century Cures Act, is an FDA mechanism for expediting the development and review of certain medical devices. It does not create a new regulatory pathway. A device still clears through a 510(k), De Novo, or PMA route. The designation adds a set of procedural benefits—interactive communication, sprint review, and priority assignment—that can compress the premarket timeline.

What it is not: a guarantee of coverage, a payment category, or a substitute for demonstrating reasonable assurance of safety and effectiveness. The FDA grants the designation; CMS makes coverage and payment decisions independently. That distinction is the single biggest misconception among founders. The designation provides no shortcut to a national coverage determination or a favorable payment rate. It does, however, position the device for a separate CMS process called transitional coverage for emerging technologies (TCET), which we’ll unpack later.

Eligibility Criteria: Does Your Device Qualify?

The FDA spells out the criteria in its final guidance. You need to satisfy two conditions:

  1. The device must provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. The comparison is against the current standard of care, not just any alternative.
  2. The device must meet one of the following: (a) it represents a breakthrough technology, (b) no approved or cleared alternatives exist, (c) it offers significant advantages over existing alternatives, or (d) its availability is in the best interest of patients.

“Breakthrough technology” is not a synonym for novel. The FDA expects a reasonable expectation that the device will deliver a clinically meaningful advantage. You can base this on bench data, animal studies, or early clinical data. The bar is lower than for a PMA approval, but you need more than a hunch. A common mistake: claiming a new mechanism without tying it to a concrete patient outcome. If you’re building a diagnostic, show how the result changes treatment decisions. If you’re building a therapeutic, show a reduction in mortality or a major morbidity endpoint.

Practical tip: Before drafting the Q-Submission request, write a one-page table that maps your clinical evidence to each criterion. The FDA’s review team will look for that alignment.

Benefits During FDA Review

The program’s value lies in three concrete benefits:

One overlooked benefit: the FDA can agree to accept manufacturing information later in the review cycle, allowing you to finalize the facility while the clinical data is under evaluation. This is not a waiver; it’s a scheduling tool. Use it if you’re still locking in a contract manufacturer.

The Reimbursement Reality: Medicare Coverage and Payment

After 510(k) clearance or De Novo grant, CMS makes its own call. The Breakthrough Device Designation triggers eligibility for a voluntary Medicare coverage pathway called transitional coverage for emerging technologies (TCET). TCET is a proposed rule, not a final policy, but its framework is instructive. The idea: CMS will issue a national coverage determination (NCD) within 6 months of FDA authorization for devices that fit the TCET criteria. The manufacturer must opt in and provide a clinical evidence development plan.

Even with TCET, coverage is not automatic. CMS can still decide the evidence is insufficient and decline an NCD. If that happens, local Medicare Administrative Contractors (MACs) may issue local coverage determinations (LCDs) on a case-by-case basis. That process is slower and less predictable.

For payment, a new device typically gets mapped to an existing HCPCS code or an unlisted code. If no appropriate code exists, you’ll need to apply for a new Level II HCPCS code, which takes 6-12 months. In the meantime, you’re billing with an unlisted code and justifying each claim manually. The Breakthrough designation does not accelerate HCPCS code assignment.

Here’s the sequence that will actually happen, assuming a De Novo classification:

  1. FDA grants Breakthrough Device Designation.
  2. You submit the De Novo request and receive marketing authorization.
  3. You request a new HCPCS code from CMS (if no suitable code exists).
  4. You submit a TCET application to CMS, if the program is active.
  5. CMS reviews your evidence and may issue a national coverage decision.

At each step, the designation opens doors, but it never removes the need for a strong clinical and economic dossier. The person leading your market access work should own this timeline from day one.

Actionable Takeaways

Breakthrough Device Designation is a powerful accelerator for FDA review. It is not a reimbursement strategy. Founders who treat it as one wind up six months post-clearance with a device, a 510(k) letter, and no payment pathway. Build the market access plan in parallel with the regulatory submission, and use the designation for what it does best: giving you faster, more direct access to the reviewers who decide your fate.

Related reading